Early Phase 1 Hepatitis B Trial, Recruiting NCT07328711 Sponsor: Peking University People's Hospital Condition: Hepatitis B
Back to Hepatitis B

Early Phase 1 Hepatitis B Trial, Recruiting

NCT07328711
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 60 years old (inclusive)
  • People who have tested positive for hepatitis B (via HBsAg and/or HBV DNA blood tests) for more than 6 months
  • People whose hepatitis B surface antigen (HBsAg) has dropped to an undetectable level after completing a treatment regimen based on a medicine called PegIFN-alpha (a type of interferon therapy)
  • People who have tested negative for a specific hepatitis B marker (HBeAg) and have a very low level of hepatitis B virus in their blood
  • People who are willing to follow the trial requirements and sign a consent form agreeing to take part

Who may not be able to join:

  • People who have, or have previously had, advanced liver disease where the liver has stopped working properly (called decompensated cirrhosis)
  • People whose hepatitis B surface antigen cleared on its own, or as a result of taking antiviral tablet treatments (rather than through interferon-based therapy)
  • People who are also infected with another virus, such as hepatitis A, C, D, or E, or HIV
  • People with serious ongoing physical or mental health conditions apart from hepatitis B — including uncontrolled kidney, heart, lung, blood vessel, nerve, digestive, or severe metabolic conditions; immune system disorders; serious infections; or current, suspected, or past cancer
  • People who have used steroid medications, immune-suppressing drugs, or chemotherapy in the 6 months before enrolling, or who are currently using them
  • People who have other liver conditions at the same time, such as alcohol-related liver disease or autoimmune liver disease
  • People with a Body Mass Index (BMI) above 28 kg/m² (confirm with trial site if unsure how this is calculated)
  • People the trial doctor considers unsuitable for any other reason, including concerns about their ability to follow the trial requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 8613810254109

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Peking University People's Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The sustained HBsAg seroclearance rate (HBsAg < 0.05 IU/mL) at 48 weeks after initial HBsAg seroclearance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov